WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018006069) IMPROVED FORMULATIONS FOR TRANSDERMAL PHARMACEUTICAL SYSTEMS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/006069    International Application No.:    PCT/US2017/040488
Publication Date: 04.01.2018 International Filing Date: 30.06.2017
IPC:
A61K 9/00 (2006.01), A61K 9/70 (2006.01), A61K 31/4045 (2006.01)
Applicants: TEVA PHARMACEUTICALS INTERNATIONAL GMBH [CH/CH]; Schlusselstrasse 12 8645 Rapperswil-Jona (CH).
DRAGER, Anthony [US/US]; (US).
GINGRICH, Diane [US/US]; (US).
WATTAMWAR, Paritosh [US/US]; (US)
Inventors: DRAGER, Anthony; (US).
GINGRICH, Diane; (US).
WATTAMWAR, Paritosh; (US)
Agent: VALLA, S., Maurice; (US).
LODISE, Stephanie, A.; (US).
VALLA, S., Maurice; (US)
Priority Data:
62/356,659 30.06.2016 US
62/356,665 30.06.2016 US
Title (EN) IMPROVED FORMULATIONS FOR TRANSDERMAL PHARMACEUTICAL SYSTEMS
(FR) FORMULE AMÉLIORÉES POUR SYSTÈMES TRANSDERMIQUES DE DISTRIBUTION DE MÉDICAMENTS.
Abstract: front page image
(EN)The present disclosure provides hydrogel compositions comprising an active pharmaceutical ingredient (or pharmaceutically acceptable salt thereof), a solubilizing agent, and a C12 to C14 saturated fatty acid, a C6 to C10 saturated fatty acid, a C6 to C30 unsaturated fatty acid, or a combination thereof. The hydrogel compositions of the disclosure have molar acid-base ratios of between about 0.8 and 1.05. Methods for producing and using these hydrogel compositions are also described. The active pharmaceutical ingredient may be sumatriptan, and the hydrogel compositions may be used in methods for treating sumatriptan responsive states, such as migraines, with transdermal patches.
(FR)Les composés d'hydrogel comprenant un ingrédient pharmaceutique actif (ou un sel comparable de celui-ci), un agent de solubilisation et un acide gras saturé C 12 à C 14 , un acide gras saturé C 6 à C 10 , un acide gras insaturé C 6 à C 30 , ou une combinaison de ceux-ci. Les compositions d'hydrogel de l'invention a des rapports molaires acide-base compris entre 0,8 et 1,05. Les procédés de production et d'utilisation de ces composés d'hydrogel sont également discutés. L'ingrédient pharmaceutique actif étant le sumatriptan, les composés d'hydrogel sont utilisés dans des procédés pour traiter des conditions sensibles au sumatriptan, telles que les migraines, avec des timbres transdermiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)